AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform ... apply them and then scale them at pace into the ...

By implementing strategies such as fine-tuning smaller models and real-time AI cost monitoring, financial institutions can ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

Victor Basta, Managing Partner of Artis Partners, believes we may be in the midst of the next round of "Zombie Unicorns." ...

In a potentially major breakthrough for regenerative medicine, scientists at MIT have developed a way to convert skin cells ...

This spoofed email will appear to the user to have come from simply “Co-pilot.” Users may have some familiarity with using Copilot to perform a myriad of tasks such as transcribing emails or drafting ...

There's one risk that's proposed as being a major threat to Bitcoin that is almost certainly highly overblown. Let's analyze ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.

Measuring an antenna’s radiation properties is important, especially when it comes to complying with regulations and system ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

FY2025 results show strong revenue growth, with cloud services up 10% y/y and total revenue up 6% y/y to $14.1 bn. Read more ...